io biotech aps logo

IO Biotech ApS

IO Biotech is a clinical stage biotechnology company that engages in developing disruptive immunotherapies for cancer vaccines. IO Biotech ApS is developing a novel immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses.

IO Biotech ApS, was established as part of the Copenhagen Spin-outs project, and utilizes technology and vaccine developed at Centre for Immune Therapy at Herlev Hospital.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.iobiotech.com
Founded2014
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
Ole Maaloes Vej 3DK-2200
Copenhagen N
Denmark
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/io-biotech” connections=”true” suffix=””]

Pipeline

IDO Cancer vaccine activates the immune systems killer cells to recognize a damaging IDO protein. When the immune system discovers IDO infected cells in the body, the killer cells set out to render the infected cells harmless.

IO101 is a peptide vaccine encompassing an HLA-A2-restricted, 9 amino acid IDO-derived CD8+ T-cell epitope. A first-in-man clinical phase I vaccination trial using IO101 was conducted. The vaccine was well tolerated with manageable side effects and no CTCAE grade 3/4 toxicities.

IO101 was the basis for the discovery of IO102, a anti-cancer therapy containing a 21-mer IDO-derived peptide.

IO102 is a anti-cancer therapy containing a 21-mer IDO-derived peptide. it is a disruptive immune therapy with dual mode of action killing both cancer and normal cells with immune suppressive functions.

IO Biotech has entered into a clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDAë (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer.

IO103 is a anti-cancer therapy containing an XX-mer PD-L1-derived peptide.

In Mar 2018, IO Biotech signs clinical collaborative agreement with Merck & Co., Inc., under the terms with MSD, IO Biotech to conduct an international Phase 1/2 study to evaluate the combination of IO102 with MSDs anti-PD-1 therapy, KEYTRUDA.

In Jan 2016, IO Biotech raised ‹11 Mn Series A financing round from new investor Lundbeckfonden as well as existing investor Novo A/S. Earlier, in 2014, IO Biotech received pre-seed grants from Novo Seeds to fund phase II development of its IDO vaccine.